Search Result

Results for "

Hyperlipidemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (1) Acyltransferase (3) Antibiotic (1) Biochemical Assay Reagents (1) Calcium Channel (1) Cannabinoid Receptor (1) COX (1) Endogenous Metabolite (1) Fatty Acid Synthase (FASN) (2) FXR (2) HMG-CoA Reductase (HMGCR) (1) LXR (1) PPAR (2) Ser/Thr Protease (10) Small Interfering RNA (siRNA) (3) STAT (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (11) Endocrinology (2) Infection (1) Inflammation/Immunology (2) Metabolic Disease (23) Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119858

Acetiromate

Others Metabolic Disease

Acetiromate is a thyroxine analogue. Acetiromate is an antilipidemic drug for hyperlipidemia .

Acetiromate	Others	Metabolic Disease
Acetiromate is a thyroxine analogue. Acetiromate is an antilipidemic drug for hyperlipidemia .

HY-116977

Binifibrate	Others	Metabolic Disease
Binifibrate is an active compound and has a beneficial effect on lipoprotein metabolism. Binifibrate can be used for the research of hyperlipidemia .

HY-128334

PCSK9 modulator-2	Ser/Thr Protease	Metabolic Disease
PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC₅₀ value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .

HY-146084

PCSK9 modulator-3	Ser/Thr Protease	Metabolic Disease
PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC₅₀ value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .

HY-146085

PCSK9 modulator-4	Ser/Thr Protease	Metabolic Disease
PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC₅₀ value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia .

HY-P99773

Ongericimab JS002	Ser/Thr Protease	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-132591A

Inclisiran sodium ALN-PCSsc sodium	Small Interfering RNA (siRNA) Ser/Thr Protease	Cardiovascular Disease
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran sodium can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-143221

AS-Inclisiran sodium	Ser/Thr Protease	Cardiovascular Disease
AS-Inclisiran sodium is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-132591

Inclisiran ALN-PCSsc	Small Interfering RNA (siRNA) Ser/Thr Protease	Cardiovascular Disease
Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-135592

LY88074 Methyl ether	Others	Endocrinology
LY88074 Methyl ether (Example 2) is useful for the inhibition of the various estrogen deficient conditions, which are associated with estrogendeprivation syndrome including osteoporosis and hyperlipidemia .

HY-135583

LY88074 Trimethyl ether	Others	Endocrinology
LY88074 Trimethyl ether (Example 1) is useful for the inhibition of the various estrogen deficient conditions, which are associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia .

HY-150223

GalNAc unconjugated/naked Inclisiran	Small Interfering RNA (siRNA) Ser/Thr Protease	Cardiovascular Disease
GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research .

HY-106818A

Monatepil maleate AJ-2615	Acyltransferase Calcium Channel	Cardiovascular Disease Metabolic Disease
Monatepil maleate (AJ-2615) is a potent and orally active Ca ²⁺-channel antagonist and a noncompetitive ACAT inhibitor. Monatepil maleate decreases blood pressure and improves plasma lipid metabolism. Monatepil maleate has the potential for the research of hyperlipidemia .

HY-142917

THR-β agonist 4	Others	Metabolic Disease
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .

HY-143613

THR-β agonist 2	Others	Metabolic Disease
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .

HY-143614

THR-β agonist 3	Others	Metabolic Disease
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .

HY-152221

PCSK9-IN-10	Ser/Thr Protease	Metabolic Disease
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC₅₀ value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .

HY-147246

Berberine ursodeoxycholate HTD1801; BUDCA	Others	Metabolic Disease
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .

HY-N0236

Corylin 4 Publications Verification	Antibiotic STAT	Infection Metabolic Disease Cancer
Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways .

HY-N0799

Protodioscin	Endogenous Metabolite	Cancer
Protodioscin, a major steroidal saponin in Trigonella foenum-graecum Linn., has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties.

HY-148874

FXR antagonist 2	FXR	Metabolic Disease
FXR antagonist 2 (compound A-26) is a diarylamide derivative, as well as a moderate FXR antagonist. FXR antagonist 2 can be used in the study of hyperlipidemia and type 2 diabetes .

HY-B1068

Tyloxapol 1 Publications Verification Triton WR1339	Biochemical Assay Reagents	Metabolic Disease
Tyloxapol (Triton WR1339) is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol (Triton WR1339) is used to induce hyperlipidemia in animals .

HY-N0458

Pedunculoside

Fatty Acid Synthase (FASN) Metabolic Disease

Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

Pedunculoside	Fatty Acid Synthase (FASN)	Metabolic Disease
Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

HY-N2953

Borapetoside E	Fatty Acid Synthase (FASN)	Metabolic Disease
Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .

HY-139134

S-2E	HMG-CoA Reductase (HMGCR) Acetyl-CoA Carboxylase	Cardiovascular Disease
S-2E is an orally active and noncompetitive HMG-CoA reductase and acetyl-CoA carboxylase inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research .

HY-103327

MJ15	Cannabinoid Receptor	Metabolic Disease
MJ15 is a potent and selective CB1 receptor antagonist with a K_i of 27.2 pM and an IC₅₀ of 118.9 pM for rat CB1 receptors. MJ15 exhibits potency in obesity and hyperlipidemia models. MJ15 inhibits food intake and increases in body weight in diet-induced obese rats and mice .

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-14739

Choline Fenofibrate ABT-335	PPAR COX	Cardiovascular Disease
Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .

HY-103479

GOAT-IN-1	Acyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-143223

AS(3n-2)-Inclisiran	Ser/Thr Protease	Others
AS(3n-2)-Inclisiran is the antisense of Inclisiran with 3 N random site after the 2 bp spacer. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9 .

HY-155525

Anti-NASH agent 1	PPAR	Metabolic Disease Inflammation/Immunology
Anti-NASH agent 1 (compound 3d)，a derivative of Elafibranor (HY-16737)，is a potent agonist of PPAR-α/δ，targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia，liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect .

HY-143220

SS(no Galnac)-Inclisiran sodium	Others	Cardiovascular Disease
SS(no Galnac)-Inclisiran (sodium) is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9 .

HY-15197

ABT-046	Acyltransferase	Metabolic Disease
ABT-046 is a potent, selective, and orally active acyl CoA:diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC₅₀s of both 8 nM against human and mouse DGAT-1 .

HY-146288

LXR agonist 2	LXR	Metabolic Disease
LXR agonist 2 (compound 18rr) is a potent LXR (liver X receptor) agonist. LXR agonist 2 can stabilize NCOA1 (co-activator), leading to LXR agonism .

Ongericimab JS002	Ser/Thr Protease	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

Corylin 4 Publications Verification	Infection Structural Classification Monophenols Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Psoralea corylifolia L. Plants Disease Research Fields Isoflavones	Antibiotic STAT
Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways .

Protodioscin	Classification of Application Fields Leguminosae Source classification Plants Endogenous metabolite Disease Research Fields Trigonella foenum-graecum Linn. Steroids Cancer	Endogenous Metabolite
Protodioscin, a major steroidal saponin in Trigonella foenum-graecum Linn., has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties.

Pedunculoside	Aquifoliaceae Triterpenes Classification of Application Fields Terpenoids Ilex rotunda Thunb. Source classification Metabolic Disease Plants Disease Research Fields	Fatty Acid Synthase (FASN)
Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

Borapetoside E	Structural Classification Natural Products Source classification Plants Menispermaceae Tinospora crispa (L.) Hook. f. et Thoms	Fatty Acid Synthase (FASN)
Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Hyperlipidemia

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Natural
Products